In a study of the efficacy of the extract of frankincense–myrrh compound in the regulation of antitumor immune response in the hepatocellular carcinoma (HCC) model, it was found that a non-toxic dose of the extract of frankincense–myrrh compound (0.5 mg⋅mL−1) could significantly inhibit the activation of the NF-κB and STAT3 signals of the liver cancer cell line HCCLM3 and Hepa1-6 induced by the cytokine (TNF-α or IL-6), and inhibit the activation of the NF-κB and STAT3 signals in the co-culture system with the CD8 + NKG2D + cells. The gene discussed is STAT3; the disease is liver cancer.